June 2026
Depression
What June 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research in June 2026 on depression focused heavily on treatment-resistant depression (TRD), with consistent evidence that esketamine and ketamine produce rapid, robust antidepressant effects, and that psilocybin-assisted therapy induces short-term improvement. However, the evidence is limited by small sample sizes, short follow-up durations, and a lack of long-term safety data beyond 12 months.
Confidence in the evidence
Moderate- Multiple reviews and meta-analyses (e.g., article_ids 27728, 28900, 35752) consistently report rapid and sustained antidepressant effects for psilocybin, ketamine, and esketamine in TRD.
- Several studies are reviews or secondary analyses rather than large-scale RCTs, and many have small sample sizes (e.g., article_id 28904 with n=5).
- Real-world evidence (article_id 28901) and a target trial emulation (article_id 34486) support effectiveness, but long-term data beyond 12 months are lacking.
- Preclinical studies (article_id 27727) show null effects for microdosing, and a case report (article_id 28677) provides only anecdotal evidence.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations. 2026 | review | — | Supports | Psilocybin-assisted therapy and ketamine/esketamine show rapid and robust antidepressant effects in TRD, with psilocybin inducing short-term improvement persisting for weeks to months. |
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical | — | No effect | Chronic psilocin microdosing did not affect depressive-like behavior, sociability, or neurogenesis in rats. |
| Esketamine multi-omic biomarker evaluation in major depressive disorder (EMBER-MDD): concept, objectives and methodologies of a non-clinical investigator-initiated study. 2026 | observational | 420 | Unclear | This is a protocol for a biomarker study; no results are reported yet. |
| Ketamine renaissance: Expanding horizons from anesthesia to depression and pain 2026 | review | — | Supports | Ketamine shows rapid antidepressant action in TRD, but long-term safety and standardization issues remain unresolved. |
| Comprehensive Systematic Review of Esketamine Nasal Spray as a Standalone Rapid-Acting Treatment for Treatment-Resistant Depression: Integrating Clinical Trial Data and Emerging Real-World Evidence on Efficacy, Safety, And Relapse Prevention 2026 | review | — | Supports | Esketamine nasal spray reduces depressive symptoms more effectively than placebo and other treatments, with effects seen within days and lasting weeks to months; side effects were mild to moderate. |
| Intrinsic excitation-inhibition imbalance in major depressive disorder. 2026 | observational | 705 | Supports | MDD patients showed reduced cortical excitation-inhibition balance, and ketamine treatment altered this balance in a small clinical trial subset. |
| Rapid clinical improvement after intravenous ketamine in an adolescent with treatment-resistant depression, severe obesity, and pseudo-Cushing syndrome: A case report. 2026 | case report | 1 | Supports | Intravenous ketamine led to rapid clinical improvement in this adolescent patient. |
| Vaporized mebufotenin leads to improvement in treatment‐resistant depression 2026 | RCT | — | Supports | Vaporized mebufotenin (5-MeO-DMT) was more effective than placebo in improving depressive symptoms in a Phase 2b trial. |
| Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process 2026 | review | — | Supports | Intranasal esketamine is a novel therapeutic approach for TRD, with a review of its mechanism, adverse effects, and safe administration. |
| Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram 2026 | observational | — | Mixed | Psilocybin increased brain network reconfiguration under perturbation, while escitalopram decreased it, suggesting distinct neural changes after each treatment. |
| Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. 2026 | review | — | Supports | Psilocybin has advanced to late-stage trials, and rapid-acting treatments including psychedelics and neuromodulation show promise, but limitations like unblinding and scalability remain. |
| Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants. 2026 | RCT | 16 | Unclear | Oral S-ketamine has poor bioavailability (9-12%) and different metabolite profiles compared to intravenous, raising safety and efficacy concerns for TRD. |
| Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study 2026 | observational | 210 | Supports | Esketamine was associated with substantial antidepressant improvement, with men showing modestly better response than women at 3 months. |
| COMPARING ROUTES OF KETAMINE ADMINISTRATION IN TREATMENT-RESISTANT DEPRESSION: EFFICACY, SAFETY, AND OPTIMIZATION OF DOSING STRATEGIES 2026 | review | — | Supports | IV and intranasal routes of ketamine/esketamine are best-supported for rapid response in TRD, but require monitoring for side effects. |
| PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW 2026 | review | — | Supports | Psilocybin-assisted therapy shows rapid onset of action and long-term benefits up to 6-12 months, with improvement in anhedonia and anxiety. |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | preclinical | — | Supports | Blocking 5-HT2B receptors abolished psilocybin's rapid and sustained antidepressant-like effects in the forced swim test, suggesting this receptor mediates psilocybin's efficacy. |
| Changes in hierarchical brain dynamics of rumination following mindfulness-based cognitive therapy for depression 2026 | RCT | 80 | Supports | Mindfulness-based cognitive therapy increased brain hierarchy during rumination, which was related to clinical improvement. |
| Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry 2026 | observational | — | Supports | Real-world data from the enTRD registry show effectiveness and safety of intranasal esketamine for TRD. |
| Ketamine and Esketamine in Depression: Current Evidence on Mechanisms, Efficacy, Safety and Clinical Use – A Review 2026 | review | — | Supports | Current evidence indicates ketamine and esketamine are effective rapid-acting antidepressants for TRD, but limitations in data and need for further research are emphasized. |
| Treatment-Resistant Depression: A Psychiatry Perspective on Pathophysiological Mechanisms, Biomarkers, and Novel Therapeutic Frontiers 2026 | review | — | Supports | Emerging therapeutic frontiers for TRD include rapid-acting antidepressants, neuromodulation, and psychedelic-assisted therapy, with a need for personalized approaches. |
| Effects of Esketamine on EEG temporal dynamics in patients with depression 2026 | observational | 5 | Supports | Esketamine administration was associated with reduced alpha power in EEG and increased subjective happiness and highness within 90 minutes. |
| Association of Esketamine use with mortality and clinical outcomes in patients with cancer-related depression: A target trial emulation. 2026 | observational | 3502 | Supports | Esketamine initiation was associated with lower 2-year all-cause mortality and fewer ER/ICU visits compared to oral antidepressants alone in cancer-related depression. |
| Comparative network pharmacology analysis of ketamine and xanomeline in major depressive disorder: Shared and distinct molecular mechanisms. 2026 | theoretical | — | Unclear | Network pharmacology identified shared and distinct molecular pathways for ketamine and xanomeline in MDD, with EGFR, IGF1R, and SRC as common core targets. |
| Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 | RCT | — | Mixed | Women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia; sexual dysfunction was lower with psilocybin. |
| How do the CANMAT 2023 guidelines address treatment-resistant depression in adults? 2026 | review | — | Supports | CANMAT 2023 guidelines include modest use of ketamine and esketamine for TRD, but highlight the need for further studies on long-term efficacy. |
Psilocybin-assisted therapy and ketamine/esketamine show rapid and robust antidepressant effects in TRD, with psilocybin inducing short-term improvement persisting for weeks to months.
review
Chronic psilocin microdosing did not affect depressive-like behavior, sociability, or neurogenesis in rats.
preclinical
This is a protocol for a biomarker study; no results are reported yet.
observational · Sample size: 420
Ketamine shows rapid antidepressant action in TRD, but long-term safety and standardization issues remain unresolved.
review
Esketamine nasal spray reduces depressive symptoms more effectively than placebo and other treatments, with effects seen within days and lasting weeks to months; side effects were mild to moderate.
review
MDD patients showed reduced cortical excitation-inhibition balance, and ketamine treatment altered this balance in a small clinical trial subset.
observational · Sample size: 705
Intravenous ketamine led to rapid clinical improvement in this adolescent patient.
case report · Sample size: 1
Vaporized mebufotenin (5-MeO-DMT) was more effective than placebo in improving depressive symptoms in a Phase 2b trial.
RCT
Intranasal esketamine is a novel therapeutic approach for TRD, with a review of its mechanism, adverse effects, and safe administration.
review
Psilocybin increased brain network reconfiguration under perturbation, while escitalopram decreased it, suggesting distinct neural changes after each treatment.
observational
Psilocybin has advanced to late-stage trials, and rapid-acting treatments including psychedelics and neuromodulation show promise, but limitations like unblinding and scalability remain.
review
Oral S-ketamine has poor bioavailability (9-12%) and different metabolite profiles compared to intravenous, raising safety and efficacy concerns for TRD.
RCT · Sample size: 16
Esketamine was associated with substantial antidepressant improvement, with men showing modestly better response than women at 3 months.
observational · Sample size: 210
IV and intranasal routes of ketamine/esketamine are best-supported for rapid response in TRD, but require monitoring for side effects.
review
Psilocybin-assisted therapy shows rapid onset of action and long-term benefits up to 6-12 months, with improvement in anhedonia and anxiety.
review
Blocking 5-HT2B receptors abolished psilocybin's rapid and sustained antidepressant-like effects in the forced swim test, suggesting this receptor mediates psilocybin's efficacy.
preclinical
Mindfulness-based cognitive therapy increased brain hierarchy during rumination, which was related to clinical improvement.
RCT · Sample size: 80
Real-world data from the enTRD registry show effectiveness and safety of intranasal esketamine for TRD.
observational
Current evidence indicates ketamine and esketamine are effective rapid-acting antidepressants for TRD, but limitations in data and need for further research are emphasized.
review
Emerging therapeutic frontiers for TRD include rapid-acting antidepressants, neuromodulation, and psychedelic-assisted therapy, with a need for personalized approaches.
review
Esketamine administration was associated with reduced alpha power in EEG and increased subjective happiness and highness within 90 minutes.
observational · Sample size: 5
Esketamine initiation was associated with lower 2-year all-cause mortality and fewer ER/ICU visits compared to oral antidepressants alone in cancer-related depression.
observational · Sample size: 3502
Network pharmacology identified shared and distinct molecular pathways for ketamine and xanomeline in MDD, with EGFR, IGF1R, and SRC as common core targets.
theoretical
Women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia; sexual dysfunction was lower with psilocybin.
RCT
CANMAT 2023 guidelines include modest use of ketamine and esketamine for TRD, but highlight the need for further studies on long-term efficacy.
review
Points of agreement
- Esketamine and ketamine are consistently reported as effective rapid-acting treatments for TRD, with benefits seen within days.
- Psilocybin-assisted therapy shows rapid and sustained antidepressant effects in TRD, with improvements lasting weeks to months.
- Multiple reviews highlight the need for more long-term safety and efficacy data beyond 12 months.
- Real-world studies and registry data support the effectiveness of esketamine in clinical practice.
Conflicts
- Preclinical microdosing study (article_id 27727) found no behavioral effects, contrasting with clinical findings for full-dose psychedelics.
- Sex differences in response to esketamine were modest and not consistently significant across age groups (article_id 28901).
- Oral S-ketamine shows poor bioavailability and different metabolite profiles compared to IV, raising questions about optimal route (article_id 28649).
Gaps
- Long-term safety and efficacy data beyond 12 months are lacking for most psychedelic and ketamine treatments.
- Most studies have small sample sizes, and many are reviews rather than large-scale RCTs.
- Blinding is a challenge in psychedelic trials due to subjective effects.
- Optimal dosing strategies and administration routes for ketamine/esketamine are not fully standardized.
- Biomarker studies (e.g., EMBER-MDD) are still in protocol phase with no results yet.
- Sex- and age-specific treatment responses are underexplored.